Daniell Richard 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
TEVA EVP Daniell Richard Sells 17,295 Shares
What Happened
Daniell Richard, EVP, Europe Commercial at Teva Pharmaceutical Industries (TEVA), had 17,295 restricted share units vest on March 5, 2026 and those shares were converted/settled and sold the same day. The shares were sold in open-market transactions at a weighted average price of $31.67, generating proceeds of approximately $547,705. The filing shows the derivative settlement/conversion (code M) and the subsequent sale (code S); some shares were used to cover tax withholding tied to the vesting.
Key Details
- Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely).
- Sale: 17,295 shares sold, weighted-average price $31.67; price range reported $31.26–$32.34.
- Proceeds: ~$547,705 reported for the open-market sale.
- Derivative activity: 17,295 shares resulted from conversion/settlement of RSUs (code M); a related line shows $0 value consistent with RSU settlement/tax withholding.
- Plan/notes: Sales effected under a Rule 10b5-1 trading plan adopted Nov 10, 2025 (F3). Footnotes state all vested RSU shares were sold, including shares withheld for taxes (F4). RSU grant and vesting schedule originally granted Mar 5, 2025 (F6).
- ADS note: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 ordinary share) (F1).
- Shares owned after the transaction: not specified in the Form 4.
Context
- This was a routine vesting and immediate sale of restricted share units (cashless settlement/sale to cover taxes), not a market purchase. The disposition was executed under a pre-arranged 10b5-1 plan, which typically indicates the trades were scheduled in advance. Such sales are common following RSU vesting and do not by themselves indicate insider sentiment about the company.
Insider Transaction Report
Form 4
Daniell Richard
EVP, Europe Commercial
Transactions
- Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-05+17,295→ 103,050 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-05$31.67/sh−17,295$547,705→ 85,755 total - Exercise/Conversion
Restricted Share Units
[F2][F6][F1]2026-03-05−17,295→ 51,887 total→ Ordinary Shares (17,295 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
- [F4]Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 5, 2025, with 17,295 vested on March 5, 2026, 17,295 vesting on each of March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029.
Signature
/s/ Dov Bergwerl as attorney-in-fact for Richard Daniell|2026-03-09